Therapy selection for Hodgkin lymphoma in sickle cell disease: balancing risks and benefits

Advances in treatment have reduced mortality from Hodgkin lymphoma; therefore, greater attention should be focused on minimizing the late effects. A variety of risk-adapted treatment regimens exist that prioritize disease presentation but not patient-specific comorbidities. Herein, we describe a patient with sickle cell disease diagnosed with Hodgkin lymphoma and the considerations made in treatment planning to minimize therapy-related acute toxicity and late effects that overlap with the patient's preexisting sickle cell disease complications.

Automated summary

Advancements in treatment have reduced mortality rates of Hodgkin lymphoma, necessitating greater focus on minimizing long-term effects. Currently, treatment regimens prioritize disease presentation rather than patient-specific comorbidities. This article discusses the case of a patient with sickle cell disease and Hodgkin lymphoma, outlining considerations made in treatment planning to minimize therapy-related acute toxicity and late effects that overlap with the patient's existing sickle cell disease complications.